Summary
- Profile Type
- Technology request
- POD Reference
- TRDK20240912003
- Term of Validity
- 12 September 2024 - 12 September 2025
- Company's Country
- Denmark
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A Danish Start-Up has developed and patented a novel Oral drug delivery concept based on natures materials and demonstrated experimentally the reproducible delivery properties of the gastro-resistant encapsulation material. This material can be used for oral delivery of Nutraceuticals and Biopharmaceuticals to the intestine. A major potential will be treatment of IBS. The company is looking for a development partner with experience in enzymes and shaping dietary fibers or that is focused on IBD.
- Full Description
-
A Danish company has invented and patented a novel oral drug delivery concept based on dietary fibers and their digesting enzymes. The encapsulation contrasts with other marketed gastro-resistant delivery platforms in being based on food-grade ingredients. The company has performed the background research showing that its composite system has a reproducible release profile, which robustly can be engineered to deliver anywhere in the late small intestine and the large intestine (colon). The reproducibility suggests that it can provide better delivery statistics than existing oral delivery methods and thus improve the efficacy of nutraceuticals and hereby lift such products to a higher value category.
A major medical need and business opportunity with the encapsulation is estimated to be for treatments of irritable bowel syndrome (IBS) - a major disease with few treatment opportunities.
The company is seeking a business partner which can collaborate on finalizing the capsule production process and ideally has a nutraceutical needing an effective encapsulation. - Advantages and Innovations
-
The encapsulation is made from food-grade ingredients and does not impose any restrictions on the dose. This solves a problem with the existing gastro-resistant encapsulations which either have a limited daily intake due to its potential adverse effect or do not provide a reliable targeted delivery.
In the case of IBD many patients have a lower than normal pH in the colon. The company´s tecnology offers delivery to the intestine of such IBD patients. No marketed gastro-resistant encapsulations technology offers this capability. - Stage of Development
- Under development
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR description
- The company is looking for industrial partners with experience in enzymes and bacterial cellulose and preferably also have one or more nutraceutical/drug to be encapsulated by an effective Gastro-resistant enteric encapsulation. Alternatively the company is looking for a pharmaceutical company that focuses on the development of treatments for IBD.
Partner Sought
- Expected Role of a Partner
-
The partner company is expected to provide industrial experience in enzymes and bacterial cellulose and preferably also have one or more nutraceutical to be encapsulated by an effective Gastro-resistant enteric encapsulation.
The company is looking for partner(s) for developing / finalizing the development of its proprietary novel Oral drug delivery concept into a viable gastro-resistant enteric encapsulation for oral delivery of nutraceuticals and / or biopharmaceuticals.
Pharmaceutical companies that focus on irritable bowel syndrome (IBS) is also of major interest. - Type and Size of Partner
- SME 50 - 249
- SME 11-49
- Big company
- Type of partnership
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 03004006 - Organic Substances
- 03004001 - Agro chemicals
- 03004007 - Pharmaceutics
- 06001012 - Medical Research
- 06001015 - Pharmaceutical Products / Drugs
- Market keywords
- 05007002 - Pharmaceuticals/fine chemicals
- 05009003 - Animal health
- 05005022 - Other clinical medicine
- Sector Groups Involved
- Health
- Agri-Food
- Targeted countries
- All countries